Evaluating FAPI-04-PET/CT for Glioma Recurrence Detection
Author Information
Author(s): Dev Indraja D., Puranik Ameya D., Rangarajan Venkatesh, Patra Sukriti, Purandare Nilendu, Sahu Arpita, Choudhary Amitkumar, Bhattacharya Kajari, Gupta Tejpal, Chatterjee Abhishek, Dasgupta Archya, Moiyadi Aliasgar, Shetty Prakash, Singh Vikas, Sridhar Epari, Sahay Ayushi, Shah Aekta, Ghosh Suchismita, Choudhury Sayak, Shah Sneha, Agrawal Archi, Li Ning
Primary Institution: Tata Memorial Hospital and Advanced Center for Treatment, Research and Education in Cancer (ACTREC), Homi Bhabha National University, Mumbai, India
Hypothesis
Can FAPI-04-PET/CT effectively differentiate between recurrence and post-treatment changes in high-grade gliomas?
Conclusion
FAPI PET uptake correlated with amino acid expression to differentiate post-treatment changes from recurrence in high-grade gliomas.
Supporting Evidence
- Five patients showed concordance between FAPI expression and FET uptake suggestive of disease recurrence.
- One patient had no FAPI expression, indicating post-treatment changes.
- FAPI PET is a promising tool for differentiating between tumor recurrence and treatment effects.
Takeaway
This study looked at how well a new imaging test can tell if a brain tumor is coming back or if changes are just from treatment. It found that the new test works pretty well.
Methodology
A retrospective cohort study of six patients with WHO Grade III and IV gliomas who underwent FAPI-04-PET/CT and FET PET imaging.
Limitations
The small size of the patient cohort limits the generalizability of the findings.
Participant Demographics
Patients included 4 males and 2 females aged between 35 and 66 years, with WHO Grade III and IV gliomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website